Form 4: Vigil Neuroscience Director Booth Receives Repriced Stock Options

Director Bruce Booth receives repriced stock options from Vigil Neuroscience, Inc. under the 2021 Stock Option and Incentive Plan.

Summary

• Bruce Booth, a director at Vigil Neuroscience, Inc., received repriced stock options on May 3, 2024.
• The repricing was approved by the Issuer's Board of Directors under the 2021 Stock Option and Incentive Plan.
• The exercise price of some stock options was adjusted to $3.03 per share, representing the fair market value on the effective date.
• A total of 53,373 stock options were repriced or granted.
• Some stock options were issued in lieu of cash compensation under the Non-Employee Director Compensation Policy and are fully vested.
• Certain repriced options revert to their original exercise price if exercised during a specified Retention Period.

Sentiment

Score: 6

Explanation: The document is neutral in tone, detailing routine stock option grants and repricing. It's a standard corporate action, neither particularly positive nor negative.

Positives

• The repricing of stock options could incentivize the director to improve company performance.
• The issuance of fully vested options in lieu of cash compensation conserves company cash.

Risks

• The repriced stock options may not provide the intended incentive if the share price does not increase.
• The potential reversion of the exercise price during the Retention Period could create uncertainty.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the stock options.

Industry Context

Stock option repricing is a common practice to re-incentivize employees or directors when a company's stock price has declined. This is often seen in the biotech industry, where stock prices can be volatile due to the long development timelines and regulatory hurdles.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• Repricing of stock options is a tool used by companies like Vigil Neuroscience to maintain alignment between management and shareholder interests when the stock price has underperformed.
• The vesting schedules and exercise prices are generally comparable to those offered by similar-sized biotech companies.

Stakeholder Impact

• The stock option repricing could potentially benefit shareholders if it incentivizes the director to improve company performance and increase the stock price.
• The issuance of stock options in lieu of cash compensation could benefit the company by conserving cash.

Key Dates